Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients

Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia. AIMS: The objective of this study was to evaluate the safety and efficacy of saroglitazar 4 mg once daily in clinical practice. METHODS: This was an observational, multicenter, single-arm study. Pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Indian Heart J
Main Authors: Shetty, Sadanand R., Kumar, Soumitra, Mathur, R.P., Sharma, Kamal H., Jaiswal, Ashok D.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4382542/
https://ncbi.nlm.nih.gov/pubmed/25820046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ihj.2015.02.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados